Vertex Pharmaceuticals Enters New Partnership With RNA Expert Skyhawk TherapeuticsThe Motley Fool • 12/22/20
Vertex Announces FDA Approvals of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) and KALYDECO® (ivacaftor) for Use in People With CF With Certain Rare MutationsBusiness Wire • 12/21/20
Vertex Pharmaceuticals (VRTX) Stock Moves -0.08%: What You Should KnowZacks Investment Research • 12/18/20
Vertex Announces European Commission Approval for SYMKEVI® (tezacaftor/ivacaftor) With KALYDECO® (ivacaftor) for Eligible Children With Cystic Fibrosis Ages 6-11 YearsBusiness Wire • 11/27/20
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Jefferies London Healthcare Conference (Transcript)Seeking Alpha • 11/19/20
Vertex to Present at the Jefferies Virtual London Health Care Conference on November 19Business Wire • 11/12/20